by admin | Oct 28, 2019 | Funding
Connecticut-based microbiome therapy company Azitra recently announced a $14 million haul in Series A funding. The round was led by KdT Ventures and previous investor Bios Partners, along with Godfrey Capital and Connecticut Innovations. Azitra, which focuses on...
by admin | Oct 28, 2019 | Clinical Trials
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, announces that the first US patient has been recruited into its on-going pivotal Phase...
by admin | Oct 28, 2019 | Licensing
Chugai, one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in silico tools...
by admin | Oct 28, 2019 | Funding
Pepticom’s unique artificial intelligence (AI) technology streamlines and significantly accelerates the ability of researchers to discover advanced peptide-based drug candidates. Peptides are used in various therapies, and are recognized for being highly...
by admin | Oct 21, 2019 | Funding
Abalos Therapeutics launches with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground. Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK...